Paris - Delayed Quote EUR

TheraVet SA (ALVET.PA)

0.1085

+0.0025

(+2.36%)

At close: December 24 at 12:57:03 PM GMT+1

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

GOSSELIES, Belgium, November 18, 2024--Regulatory News: EGEIRO Pharma (ISIN : BE0974387194 - mnemo : ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, notably in Idiopathic Pulmonary Fibrosis, announces that its Board of Directors meeting on November 15, 2024 has acknowledged the resignation of Enrico Bastianelli as a Director and has decided to modify its governance. Gaëtan Terrasse has been appointed Managing Director and Emmanuel Huynh

Business Wire last month

ALVET.PA
+2.36%
TheraVet Becomes EGEIRO Pharma

GOSSELIES, Belgium, October 29, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, informs its shareholders that its Extraordinary General Meeting ("EGM") was held on Monday October 28, 2024 at 10:00 am in the offices of the Berquin law firm, 11 avenue Lloyd George, 1000 Brussels, in the presence of Simon Wheeler, Chairman of the Board of Directors.

Business Wire last month

ALVET.PA
+2.36%
TheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary Fibrosis

GOSSELIES, Belgium, September 30, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) today announces a strategic transformation project with H4Orphan aimed at creating a leader in idiopathic pulmonary fibrosis and accelerating the development of its multi-target drug candidate.

Business Wire 2 months ago

ALVET.PA
+2.36%
TheraVet Reports Its 2024 Half-year Results and Provides an Update on the Development of Its Activities

GOSSELIES, Belgium, September 12, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces its financial results ended June 30, 2024, and the publication of its half-year financial report.

Business Wire 3 months ago

ALVET.PA
+2.36%
TheraVet Announces Early Completion of Patient Recruitment of the VISCO-VET Clinical Study

GOSSELIES, Belgium, May 21, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 - Ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the early completion of the patient recruitment of its the pivotal European multicentric clinical study assessing VISCO-VET in canine osteoarthritis (VV-OA2) due to recruitment difficulties. Despite the efforts to enroll patients, the number of patients enrolled fell short of the initi

Business Wire 7 months ago

ALVET.PA
+2.36%
TheraVet Unveils Its Development Strategy to Address the Equine Market

GOSSELIES, Belgium, May 07, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 - Ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the deployment of its range of solutions in the highly dynamic competition horse segment.

Business Wire 7 months ago

ALVET.PA
+2.36%
TheraVet reports Full-Year 2023 Financial Results and Provides the Preparatory Documents for the General Meeting of June 6th, 2024

GOSSELIES, Belgium, April 23, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces its Full-Year results for the year to December 31, 2023.

Business Wire 7 months ago

ALVET.PA
+2.36%
TheraVet Reports 2023 Full Year and 2024 First Quarter Revenues

GOSSELIES, Belgium, April 10, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, reports its 2023 full year and 2024 first quarter revenues.

Business Wire 8 months ago

ALVET.PA
+2.36%
TheraVet : BIOCERA-VET® is Now Available for the Management of Dental and Orthopedics Conditions in Horses

GOSSELIES, Wallonia, Belgium, March 13, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the launch of BIOCERA-VET® Equine in countries already covered by the Company.

Business Wire 9 months ago

ALVET.PA
+2.36%
BIOCERA-VET® Is Now Available for the Management of Dental and Orthopedics Conditions in Horses

GOSSELIE, WALLONIA, Belgium, March 13, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the launch of BIOCERA-VET® Equine in countries already covered by the Company.

Business Wire 9 months ago

ALVET.PA
+2.36%
TheraVet Retains a Leading US Veterinary Consulting Firm to Help Strategize Company Growth on the US Market

GOSSELIES, Belgium, February 20, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the recruitment of Brakke Consulting to help strategize Company growth on the US market. Brakke – www.brakkeconsulting.com - is one of the leading consulting firms in the veterinary market with a solid track record of upscaling vet companies on the US market.

Business Wire 10 months ago

ALVET.PA
+2.36%
TheraVet Strengthens Its Intellectual Property With the Issuance of a Patent on VISCO-VET Technology in Europe, Israël & Singapore

GOSSELIES, Wallonia, Belgium, January 30, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces that the European Patent Office (EPO), and the Singapore and Israel patent offices granted a patent covering TheraVet VISCO-VET technology.

Business Wire 10 months ago

ALVET.PA
+2.36%
TheraVet Reports an 99% Increase in BIOCERA-VET® Units Sold in Q4 2023

GOSSELIES, Belgium & WALLONIA, Belgium, January 23, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces significant sales progression for its BIOCERA-VET® product range in the 4th quarter of 2023 year-on-year and quarter over quarter.

Business Wire 10 months ago

ALVET.PA
+2.36%
TheraVet: Commercial Launch of BIOCERA-VET® in Germany

GOSSELIES, Belgium & WALLONIA, Belgium, January 17, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces today the commercial launch of its BIOCERA-VET® products in Germany.

Business Wire 11 months ago

ALVET.PA
+2.36%
TheraVet: Agreement with Alcyon Italia for the Distribution of BIOCERA-VET® Product Line in Italy

GOSSELIES, Wallonia, Belgium, January 09, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, starts the distribution of its line of bone substitutes BIOCERA-VET® in Italy with Alcyon Italia.

Business Wire 11 months ago

ALVET.PA
+2.36%
TheraVet Reports Significant Success of Its Last Educational Webinar on Canine Osteosarcoma Co-Organized With Veterinary Instrumentation

GOSSELIES, Belgium, January 04, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, organized on December 18, 2023, in collaboration with Veterinary Instrumentation, the exclusive BIOCERA-VET® distributor in United Kingdom and Ireland, its last educational webinar of the year 2023.

Business Wire 11 months ago

ALVET.PA
+2.36%

Performance Overview

Return	ALVET.PA	CAC 40
YTD	-92.52%	-3.45%
1-Year	-92.41%	-3.78%
3-Year	-98.19%	+2.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TheraVet SA (ALVET.PA)

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

TheraVet Becomes EGEIRO Pharma

TheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary Fibrosis

TheraVet Reports Its 2024 Half-year Results and Provides an Update on the Development of Its Activities

TheraVet Announces Early Completion of Patient Recruitment of the VISCO-VET Clinical Study

TheraVet Unveils Its Development Strategy to Address the Equine Market

TheraVet reports Full-Year 2023 Financial Results and Provides the Preparatory Documents for the General Meeting of June 6th, 2024

TheraVet Reports 2023 Full Year and 2024 First Quarter Revenues

TheraVet : BIOCERA-VET® is Now Available for the Management of Dental and Orthopedics Conditions in Horses

BIOCERA-VET® Is Now Available for the Management of Dental and Orthopedics Conditions in Horses

TheraVet Retains a Leading US Veterinary Consulting Firm to Help Strategize Company Growth on the US Market

TheraVet Strengthens Its Intellectual Property With the Issuance of a Patent on VISCO-VET Technology in Europe, Israël & Singapore

TheraVet Reports an 99% Increase in BIOCERA-VET® Units Sold in Q4 2023

TheraVet: Commercial Launch of BIOCERA-VET® in Germany

TheraVet: Agreement with Alcyon Italia for the Distribution of BIOCERA-VET® Product Line in Italy

TheraVet Reports Significant Success of Its Last Educational Webinar on Canine Osteosarcoma Co-Organized With Veterinary Instrumentation

Performance Overview